In this study, we showed that RPL29 is a central protein that enables the survival of CCA under CDK4/6 inhibition, and that oxaliplatin treatment results in early degradation of RPL29 and cancer cell death, which is mediated at least partly by p53-mediated cell death. This evidence concerns the gene RPL29 and cancer.